FDA Grants Priority Review to Cladribine Tablets for the Treatment of Relapsing Forms of Multiple Sclerosis
Darmstadt, Germany, July 28, 2010 - Merck KGaA announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for Cladribine Tablets as a therapy for relapsing forms of multiple sclerosis...
Short URL: http://drugrehab.in/?p=69097
Posted by admin
on Jul 28 2010. Filed under drug applications.
You can follow any responses to this entry through the RSS 2.0.
Both comments and pings are currently closed.
